JP2001509778A - 移植片不全または対宿主性移植片病を伴わない同種異系造血幹細胞移植法 - Google Patents

移植片不全または対宿主性移植片病を伴わない同種異系造血幹細胞移植法

Info

Publication number
JP2001509778A
JP2001509778A JP51815097A JP51815097A JP2001509778A JP 2001509778 A JP2001509778 A JP 2001509778A JP 51815097 A JP51815097 A JP 51815097A JP 51815097 A JP51815097 A JP 51815097A JP 2001509778 A JP2001509778 A JP 2001509778A
Authority
JP
Japan
Prior art keywords
cells
recipient
hematopoietic
mononuclear
bone marrow
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP51815097A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001509778A5 (https=
Inventor
ケイ． ウォーラ，エドマンド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University filed Critical Emory University
Publication of JP2001509778A publication Critical patent/JP2001509778A/ja
Publication of JP2001509778A5 publication Critical patent/JP2001509778A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
    • A61K41/17—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person by ultraviolet [UV] or infrared [IR] light, X-rays or gamma rays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP51815097A 1995-11-08 1996-07-29 移植片不全または対宿主性移植片病を伴わない同種異系造血幹細胞移植法 Ceased JP2001509778A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/555,520 1995-11-08
US08/555,520 US5800539A (en) 1995-11-08 1995-11-08 Method of allogeneic hematopoietic stem cell transplantation without graft failure or graft vs. host disease
PCT/US1996/012426 WO1997017079A1 (en) 1995-11-08 1996-07-29 Method of allogeneic hematopoietic stem cell transplantation without graft failure or graft vs. host disease

Publications (2)

Publication Number Publication Date
JP2001509778A true JP2001509778A (ja) 2001-07-24
JP2001509778A5 JP2001509778A5 (https=) 2004-09-16

Family

ID=24217573

Family Applications (1)

Application Number Title Priority Date Filing Date
JP51815097A Ceased JP2001509778A (ja) 1995-11-08 1996-07-29 移植片不全または対宿主性移植片病を伴わない同種異系造血幹細胞移植法

Country Status (6)

Country Link
US (1) US5800539A (https=)
EP (1) EP0862443A1 (https=)
JP (1) JP2001509778A (https=)
AU (1) AU707211B2 (https=)
CA (1) CA2237200A1 (https=)
WO (1) WO1997017079A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006018998A1 (ja) * 2004-08-18 2006-02-23 Riken クローン哺乳動物の作成方法
WO2023277114A1 (ja) * 2021-07-02 2023-01-05 公益財団法人神戸医療産業都市推進機構 放射線照射造血幹細胞を含む医薬組成物

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8409564B2 (en) * 1999-10-05 2013-04-02 Universite De Montreal Rhodamine derivatives for photodynamic diagnosis and treatment
DE60043511D1 (de) * 1999-10-20 2010-01-21 Chugai Pharmaceutical Co Ltd Verwendung von g-csf zur hemmung der gvhd
US20020127208A1 (en) * 2000-08-31 2002-09-12 Waller Edmund K. Method of transplantation using chemotherapy-treated allogeneic cells that enhance immune responses without graft versus host disease
US6869956B2 (en) 2000-10-03 2005-03-22 Bristol-Myers Squibb Company Methods of treating inflammatory and immune diseases using inhibitors of IκB kinase (IKK)
EP1361896A2 (en) * 2001-01-23 2003-11-19 Boston Scientific Corporation Localized myocardial injection method for treating ischemic myocardium
EP2316918B1 (en) 2001-02-14 2015-07-01 Anthrogenesis Corporation Post-partum mammalian placenta, its use and placental stem cells therefrom
CA2342675A1 (en) * 2001-04-02 2002-10-02 Abdelkrim Habi Halogenated rhodamine derivatives and applications thereof
WO2003001981A2 (en) * 2001-06-29 2003-01-09 The Government Of The United State Of America As Represent By The Secretary Of The Department Of Health And Human Services Method of promoting engraftment of a donor transplant in a recipient host
US7037900B2 (en) * 2001-10-12 2006-05-02 Supergen, Inc. Composition and method for treating graft-versus-host disease
US7799324B2 (en) * 2001-12-07 2010-09-21 Geron Corporation Using undifferentiated embryonic stem cells to control the immune system
US20040224403A1 (en) * 2001-12-07 2004-11-11 Robarts Research Institute Reconstituting hematopoietic cell function using human embryonic stem cells
EP2292091A1 (en) 2002-02-13 2011-03-09 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
CA105900S (en) 2003-08-12 2006-10-19 180S Inc Frame for ear warmer
CA2548468C (en) * 2003-12-05 2012-05-29 Universite De Montreal The use of dead cell material obtained from rhodamine-based photodynamic therapy in the treatment or prevention of immunologic disorders, infections and cancers
WO2006057951A2 (en) * 2004-11-22 2006-06-01 Beth Israel Deaconess Medical Center Methods and compositions for the treatment of graft failure
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
PL2471907T3 (pl) 2005-12-29 2019-07-31 Celularity, Inc. Populacje komórek macierzystych łożyska
EP1976978A2 (en) 2005-12-29 2008-10-08 Anthrogenesis Corporation Co-culture of placental stem cells and stem cells from a second source
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20090197823A1 (en) 2006-05-09 2009-08-06 Braincells, Inc. Aliskiren modulation of neurogenesis
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8562972B2 (en) 2006-10-23 2013-10-22 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
WO2008083204A2 (en) * 2006-12-28 2008-07-10 Braincells, Inc. Modulation of neurogenesis by melatoninergic ligands
US20080171750A1 (en) * 2007-01-11 2008-07-17 Braincells, Inc. Modulation Of Neurogenesis With Use of Modafinil
WO2008097861A2 (en) * 2007-02-02 2008-08-14 Braincells, Inc. MODULATION OF NEUROGENESIS WITH BIGUANIDES AND GSK3-ß AGENTS
US20090239834A1 (en) * 2008-03-21 2009-09-24 Braincells, Inc. Mcc-257 modulation of neurogenesis
CA2734446C (en) 2008-08-22 2017-06-20 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2555783A1 (en) 2010-04-08 2013-02-13 Anthrogenesis Corporation Treatment of sarcoidosis using placental stem cells
WO2012092485A1 (en) 2010-12-31 2012-07-05 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory rna molecules
ES2707579T3 (es) 2011-06-01 2019-04-04 Celularity Inc Tratamiento del dolor usando citoblastos placentarios

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5032508A (en) * 1988-09-08 1991-07-16 Marrow-Tech, Inc. Three-dimensional cell and tissue culture system
US4869826A (en) * 1987-09-01 1989-09-26 Process Biotechnology, Inc. Cellular adsorbents for removal of viral contaminants from blood and complex protein solutions
US5147289A (en) * 1990-03-29 1992-09-15 Therakos, Inc Non-specific immune system enhancement
WO1992010198A1 (en) * 1990-12-06 1992-06-25 Johnson & Johnson Research Pty Limited Immunotherapeutic agents, compositions and methods
US5601815A (en) * 1992-08-21 1997-02-11 Schering Corp IL-4 and IL-10 to downregulate delayed-type hypersensitivity and cytokine expresion by T-cells
JP3541950B2 (ja) * 1993-05-14 2004-07-14 ザ・ウイスター・インステイテユート・オブ・アナトミー・アンド・バイオロジー 癌およびウイルス性疾患を治療するための改変化ｔａｌｌ−１０４細胞の使用
IL107483A0 (en) * 1993-11-03 1994-02-27 Yeda Res & Dev Bone marrow transplantation
IL112969A (en) * 1994-03-17 2001-05-20 Baxter Int Pharmaceutical compositions for the treatment of cancer comprising allogenic lymphocytes or their combination with a t-cell activator

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006018998A1 (ja) * 2004-08-18 2006-02-23 Riken クローン哺乳動物の作成方法
WO2023277114A1 (ja) * 2021-07-02 2023-01-05 公益財団法人神戸医療産業都市推進機構 放射線照射造血幹細胞を含む医薬組成物

Also Published As

Publication number Publication date
US5800539A (en) 1998-09-01
WO1997017079A1 (en) 1997-05-15
CA2237200A1 (en) 1997-05-15
AU707211B2 (en) 1999-07-08
AU6682696A (en) 1997-05-29
EP0862443A1 (en) 1998-09-09

Similar Documents

Publication Publication Date Title
JP2001509778A (ja) 移植片不全または対宿主性移植片病を伴わない同種異系造血幹細胞移植法
CN102600461B (zh) 给予体外部分成熟的树突细胞治疗肿瘤
JP2002507881A (ja) 樹枝状細胞前駆体のインビトロ増殖の方法およびその免疫原製造への使用
JP2013537187A (ja) 抗白血病／リンパ腫処置のための抗第三者セントラルメモリーｔ細胞の使用
JPS5829714A (ja) 血清不含およびミトゲン不含ｔ細胞生長因子およびその製造法
US20030149011A1 (en) Methods and reagents for extracorporeal immunomodulatory therapy
JP2024526837A (ja) 治療用ｎｋ細胞集団
US6213127B1 (en) Methods for treating cancer using allogeneic lymphocytes without graft vs host disease activity
JP3541950B2 (ja) 癌およびウイルス性疾患を治療するための改変化ｔａｌｌ−１０４細胞の使用
Jones et al. Cytotoxically impaired transplant recipients can efficiently resist major histocompatibility complex--matched bone marrow allografts
US20010014320A1 (en) Methods for treating cancer using allogeneic lymphocytes without graft vs host disease activity
WO2001070243A2 (en) A method for treating early breast cancer
MAckIE et al. Dose-related mechanisms of immunosuppression mediated by murine anti-CD3 monoclonal antibody in pancreatic islet cell transplantation and delayed-type hypersensitivity
JP2003508047A (ja) 移植片−対−宿主疾患を抑制するサイトカイン、細胞およびマイトジェンの使用
JP4106488B2 (ja) 同種移植片に対する免疫寛容の誘導および／または白血病処置のための、幹細胞およびｃｄ６枯渇幹細胞の使用
Bouwens Pit cells
Joshi et al. Immunotherapy of human neuroblastoma using umbilical cord blood-derived effector cells
KR20080091776A (ko) 간 기능장애 치료에 간 전구체를 이용하는 방법
CN1213143C (zh) 同源异型的造血系统重构细胞的制药应用
EP1871872B1 (en) Method for activating cd8 t cells
WO2025174885A1 (en) Compositions, methods of making, and methods of using irradiated antigen presenting cells in the treatment of health conditions
Rapaport et al. Implication of Ia-positive bone marrow interstitial stem cells in the induction of unresponsiveness to canine renal allografts
Deeg et al. Transfusion-induced allosensitization in marrow transplant recipients: Mechanisms and preventive measures
Rasmusson et al. Human mesenchymal stem cells affect IgG production induced by lipopolysaccharide, cytomegalovirus and varicella zoster virus in human spleen cells
Skiera et al. Graft engineering of G-CSF-mobilized allogeneic leukapheresis products by counterflow centrifugal elutriation after CD34 column adsorption

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070821

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20080109

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20080226